Velpatasvir

Cat. No.: HY-12530

CAS No.: 1377049-84-7

Molecular Formula: $C_{49}H_{54}N_8O_8$

Molecular Weight: 883

Target: HCV; SARS-CoV

Pathway: Anti-infection

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 146.66 mg/mL (166.09 mM; Need ultrasonic and warming)

H_2O : 1 mg/mL (1.13 mM; Need ultrasonic and warming)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.1325 mL	5.6625 mL	11.3250 mL
5 mM	0.2265 mL	1.1325 mL	2.2650 mL
10 mM	0.1133 mL	0.5663 mL	1.1325 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (2.83 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (2.83 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (2.83 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV $3CL^{pro}$ inhibitor with an IC_{50} of 2.16 μM[2].

CUSTOMER VALIDATION

- Hepatology. 2019 May;69(5):1861-1872.
- Signal Transduct Target Ther. 2021 May 29;6(1):212.
- J Gastroenterol. 2019 May;54(5):449-458.
- Sci Rep. 2019 Apr 5;9(1):5722.
- Viruses. 2018 Aug 28;10(9). pii: E462.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78.

[2]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA